PolyActiva has recently secured $40 million (AUD) in Series C funding, led by the Australian National Reconstruction Fund (NRFC), and Australia’s leading biotech investor, Brandon Capital.
The funds will support the continued clinical advancement of PolyActiva’s lead ocular implant, PA5108, as it progresses to Series 2b clinical trials in the US. In addition to advancing PA5108, PolyActiva plans to use these funds to broaden their pipeline and explore new therapeutic opportunities enabled by its proprietary PREZIA™ platform technology.